UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ...
Release Date: March 10, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
UroGen Pharma Ltd (NASDAQ:URGN) submitted a new drug application for UGN 102 ahead of schedule, with FDA review underway and a target date set for June 13th.
The Envision phase 3 trial for UGN 102 demonstrated a compelling complete response rate of 79.6% at 3 months and an 82.3% duration of response at 12 months.
UroGen Pharma Ltd (NASDAQ:URGN) reported a strong balance sheet with $241.7 million in cash equivalents and marketable securities, positioning them well for future growth.
The company achieved a 12% year-over-year increase in sales for their commercial product, Jelmyto, indicating strong market demand.
UroGen Pharma Ltd (NASDAQ:URGN) is expanding its sales force from 52 to 83 representatives in anticipation of the UGN 102 launch, demonstrating a commitment to commercial preparedness.
UroGen Pharma Ltd (NASDAQ:URGN) reported a net loss of $126.9 million for the full year 2024, an increase from the $102.2 million loss in 2023.
Research and development expenses increased significantly to $57.1 million in 2024 from $45.6 million in 2023, driven by manufacturing and regulatory expenses.
SG&A expenses rose to $121.2 million in 2024 from $93.3 million in 2023, primarily due to commercial preparation activities for UGN 102.
The company anticipates using a miscellaneous J code for UGN 102 initially, which may complicate reimbursement processes for providers.
UroGen Pharma Ltd (NASDAQ:URGN) faces potential challenges in market access and reimbursement during the initial launch period of UGN 102 due to the generic J code.
Warning! GuruFocus has detected 4 Warning Signs with URGN.
Q: You noted on the call that you anticipate approval in the recurrent setting. Do you anticipate that UGN 102 could still be used in the about 10% of patients or so that are ineligible for surgery, which would be the frontline setting, and would this then require it to be used off label? A: Liz Barrett, CEO: Yes, that would be considered off-label, so we wouldn't be able to promote there. It would be up to the physician to work with their insurance company to ensure payment. This doesn't change our revenue projections, as we still believe UGN 102 will generate over a billion dollars in revenue. Physicians have expressed a desire to make this choice, and we are considering whether to conduct clinical work in this space.
Q: On UGN 102, as you think about the potential FDA approval later this summer, how should investors think about the initial launch trajectory, perhaps relative to Gelido or other potential benchmarks? A: David Lynn, Chief Commercial Officer: We intend to continue educating our physician provider universe and maintaining support. The overall shape of the launch curve is modeled similarly to Gelido, although the absolute numbers will be larger due to the patient population. We are considering pricing in the $18,000 to $19,000 per dose range.
Q: With respect to UGN 102 and the projected reimbursement environment, can you provide additional granularity regarding the difference in reimbursement level and market access during the period immediately after launch with a generic J code versus a specific J code? A: David Lynn, Chief Commercial Officer: Initially, we anticipate using a miscellaneous J code, which may result in a longer reimbursement process of about 50 to 60 days. This will improve with a permanent J code expected by January 2026. We will support accounts through this period, similar to our approach with Jamio.
Q: Regarding the pipeline development activities, can you give us an update on how enrollment kinetics appear to be progressing in the UGN 103 program and if you still expect to report data from that trial either next year or in 2027? A: Mark Schoenberg, Chief Medical Officer: We anticipate completing enrollment for the Utopia trial this year, with data expected in 2026 and potential approval in 2027. The trial is progressing well, and we are optimistic about maintaining this timeline.
Q: Given the impressive durability that the Envision data has shown, have you stress-tested potentially higher pricing for UGN 102, and what are your payer reactions? A: Liz Barrett, CEO: We are revisiting our pricing strategy due to the impressive durability data. We believe there is an opportunity to increase pricing slightly and are conducting research to refine our assumptions.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
2 Social Media Stocks That Are Screaming Buys in June
Thanks to its nearly limitless supply of content, Reddit is taking on a significant role in the AI-powered search ecosystem. Meta Platforms plans to fully automate ads on its various properties by using AI, starting in 2026. 10 stocks we like better than Meta Platforms › After a rough start to the year, tech stocks have come roaring back. As of this writing, the tech-heavy Nasdaq Composite index has surged by more than 25% over the last two months. So with market sentiment swinging back in favor of tech stocks, let's have a closer look at two social media stocks that I believe are buys right now. First up is Reddit (NYSE: RDDT). A relative newcomer as far as social media stocks go, Reddit has only been a public company for a little over a year. However, during that time, its shares have soared by more than 250%. What's behind that excellent performance? In short, red-hot growth across the board. For the first quarter, Reddit delivered a stunning report. Highlights included: Explosive revenue growth of 61% year over year International revenue growth of 82% Average revenue per user (ARPU) 23% higher than a year earlier Daily average users (DAUs) 31% higher Gross margin now 90.5%, compared to 88.6% a year ago Net income of $26 million versus a loss of $575 million last year Reddit, which hosts hundreds of thousands of "subreddits," is part of the growing internet ecosystem that includes large language models (LLMs) like ChatGPT, search engines like Alphabet's Google, and social media networks. Since Reddit's users create millions of pieces of unique content and post subjective opinions on current events, the platform plays a key role in shaping search results and responses from LLMs. In addition, the company has gotten into the LLM game with its Reddit Answers feature, which boasts over 1 million weekly average users (WAUs). Here's the key takeaway: Reddit is an up-and-coming social media stock with a still-modest market cap of $22 billion. Its volatility and meager (for now) profits mean the stock isn't a great fit for everyone, particularly value investors. However, for long-term-oriented growth investors, Reddit is a name to consider in June. Then, there's Meta Platforms (NASDAQ: META). What I love about Meta's stock performance is that the company makes it look easy. Consider its latest earnings report. In the first quarter, the company posted: $42 billion in revenue $17 billion in net income $10 billion in free cash flow Bear in mind that those are figures for a single quarter. On a yearly basis, the company is on track to generate nearly $190 billion in revenue, meaning its total revenue this year could match -- or perhaps surpass -- iconic American companies like Ford Motor Company, General Motors, and Chevron. In addition to its excellent results, the company is also making moves for the future. Meta is spending heavily on artificial intelligence (AI) infrastructure, such as AI chips and data centers. Those investments are intended to upend the advertising landscape -- and put Meta at the heart of the digital advertising ecosystem. By 2026, the company wants to fully automate ads, allowing brands to cut out advertising-agency intermediaries altogether. What's more, Meta wants to automate the process using AI, allowing brands to customize their ads based on the viewer's location and tastes. In other words, Meta is aiming for another big leap forward -- one that could deliver another surge in revenue, profits, and free cash flow. For investors, now could be the time to load up on Meta shares, before the company begins to reap the rewards of its AI investments. However, given how far Meta has already climbed this year (at this writing, the stock is up 19% year to date), a dollar-cost-averaging strategy could be a savvy way to build a long-term position. Before you buy stock in Meta Platforms, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Meta Platforms wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Jake Lerch has positions in Alphabet, Ford Motor Company, and Reddit. The Motley Fool has positions in and recommends Alphabet, Chevron, and Meta Platforms. The Motley Fool recommends General Motors. The Motley Fool has a disclosure policy. 2 Social Media Stocks That Are Screaming Buys in June was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy
LMNA-related dilated cardiomyopathy (LMNA DCM) is one of the most aggressive forms of DCM, affecting approximately 100,000 individuals in the United States and Europe, who progress rapidly to end-stage heart failure. NVC-001 demonstrated significant benefits, including survival and cardiac function in preclinical models. IND clearance enables initiation of first-in-human, ascending-dose Phase 1/2 clinical trial in early 2026. SINGAPORE and PHILADELPHIA, June 10, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NVC-001. NVC-001 is an adeno-associated virus (AAV)-based gene therapy designed to treat LMNA-related dilated cardiomyopathy (LMNA DCM). Nuevocor plans to initiate an open-label, ascending-dose Phase 1/2 clinical trial of NVC-001 in patients with LMNA DCM. "This IND clearance marks a significant milestone in our mission to develop transformative therapies for patients with genetic cardiomyopathies by leveraging unique insights from our proprietary PrOSIA mechanobiology platform," said Dr. Yann Chong Tan, co-founder and CEO of Nuevocor. "NVC-001 is the first disease-modifying therapy for LMNA DCM designed to address the underlying mechanobiological root cause of disease. We look forward to initiating our clinical trial to bring this potentially life-changing therapy to patients." LMNA DCM is a serious genetic heart condition caused by mutations in the LMNA gene, which encodes lamin A/C – a protein essential for maintaining nuclear envelope integrity and regulating gene expression in cardiac cells. Mutations in LMNA lead to a weakening of the heart muscle, arrhythmias, and progression to end-stage heart failure. LMNA DCM is estimated to affect approximately 100,000 patients in the U.S. and Europe, representing a significant unmet medical need. NVC-001 is engineered to address the functional mechanical root cause of disease by reducing aberrant mechanical stress on the nucleus, thereby restoring nuclear envelope integrity. Nuclear envelope disruption is a hallmark of LMNA DCM. In preclinical studies, treatment with NVC-001 demonstrated significant benefits, including survival and cardiac function. The planned Phase 1/2 clinical trial is a first-in-human, 52-week open-label, multicenter, ascending-dose study designed to evaluate the safety, tolerability, and preliminary efficacy of NVC-001 in adult subjects with LMNA-DCM. NVC-001 will be administered as a one-time intravenous infusion to patients in ascending-dose cohorts. About Nuevocor Nuevocor is biotechnology company developing novel therapies for genetic cardiomyopathies driven by aberrant mechanobiology, headquartered in Singapore with an office in the U.S. and expansion to Europe. Our unique approach, enabled by our proprietary PrOSIA mechanobiology platform, surpasses the limitations of traditional gene replacement therapy – which treats individual gene mutations – to treating defects in shared disease pathways across multiple cardiomyopathies by addressing the functional root cause of disease. Nuevocor is first-in-disease by addressing genetic cardiomyopathies that are not amendable to gene replacement therapy and have no effective treatment options. ( View original content to download multimedia: SOURCE Nuevocor Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Here's How Investing $300 Per Month Can Create $50,000 in Annual Dividends
Regularly investing in the stock market can help you build up a portfolio worth more than $1 million. Investing in top growth stocks can put you in a good position to outperform the broader market. With a high enough portfolio balance, it becomes easier to generate a lot of recurring dividend income. 10 stocks we like better than Invesco QQQ Trust › Being able to live off dividend income in your retirement years can be a great goal to aim for. And by investing in the stock market, growing your portfolio, and investing in dividend-paying stocks, that can be possible. But just how does that all work? Below, I'll outline a strategy that can help you build up a strong portfolio balance over time through monthly investments of $300, and then, how that can eventually be transformed into a portfolio that's generating around $50,000 per year in dividends for you. To achieve the best returns over the long run, you'll likely want to have a position in top growth stocks. While they can be volatile, especially in the short term, over a long period of time, you should benefit from their growth and rising valuations. It can, however, be hard to pick the right growth stocks and determine the right mix of them. In order to get around this, you can simply invest in the Invesco QQQ Trust (NASDAQ: QQQ). The exchange-traded fund (ETF) will give you exposure to the top 100 non-financial stocks on the Nasdaq Stock Exchange. There's no worry about having to change your portfolio composition over the years and determining which stocks to buy and sell. All that is taken care of for you through this ETF, which does the work for you. Over the past decade, the QQQ ETF has easily beaten the S&P 500, and is a great example of why it can be an ideal investment option when pursuing long-term growth. Historically, the S&P 500 has averaged an annual total return of close to 10%. It's possible that slower annual returns may be on the horizon, given how strong the market has been in recent years. But for the Invesco QQQ Trust, which has performed much better than the market, a 10% total annual return would be a slowdown, and thus, may be a realistic percentage to use when forecasting its future performance. If you were to invest $300 per month into the fund, and it ended up averaging a 10% annual total return (compounded), then after 35 years, your portfolio balance could climb to a value of over $1.1 million. With $1.1 million, you would need to put that money into investments that yield a little more than 4.5% to generate dividend income of $50,000 per year. If your balance is not at such a high level, then you would need to target a higher yield for that to be possible, and that can result in taking on a bit too much risk. After building up your portfolio to such a large amount, it'll be important to balance both dividend income along with capital preservation; you don't want all that work of growing your portfolio to go to waste by gambling it on a risky dividend. In 35-plus years, there will be new income-generating investments to consider, but one example today of an ETF that could bring in a lot of income is the iShares International Select Dividend ETF (NYSEMKT: IDV), which yields 5.3% and gives you exposure to international companies from all over the world. This or a similar type of investment could help provide you with a sufficiently high yield to produce $50,000 in annual dividends on a $1.1 million balance, while keeping your risk relatively low. Another thing you can do to try to minimize your risk is to spread your total investment across multiple ETFs. As long as you're averaging around 4.5%, then the end result can still be the same: $50,000 in dividends per year. Regardless of what the outlook may be for the stock market this year, or for the next few years, routinely investing in it can still be an effective way of building up your wealth over the long haul. Timing the market is a risky strategy that can result in you missing out on gains. By simply making it a routine to invest in a fund like the Invesco QQQ Trust each month, you don't need to worry about external factors -- simply trust the process. There may be anxiety and poor returns in any one year, but the long-term trajectory is still likely to be a very strong and positive one. Before you buy stock in Invesco QQQ Trust, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Invesco QQQ Trust wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends Nasdaq. The Motley Fool has a disclosure policy. Here's How Investing $300 Per Month Can Create $50,000 in Annual Dividends was originally published by The Motley Fool Sign in to access your portfolio
